Section of Nutrition and Metabolism, International Agency for Research on Cancer, Lyon, France.
Colorectal Cancer Group, ONCOBELL Program, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Spain.
Gastroenterology. 2020 Apr;158(5):1300-1312.e20. doi: 10.1053/j.gastro.2019.12.020. Epub 2019 Dec 27.
BACKGROUND & AIMS: Human studies examining associations between circulating levels of insulin-like growth factor 1 (IGF1) and insulin-like growth factor binding protein 3 (IGFBP3) and colorectal cancer risk have reported inconsistent results. We conducted complementary serologic and Mendelian randomization (MR) analyses to determine whether alterations in circulating levels of IGF1 or IGFBP3 are associated with colorectal cancer development.
Serum levels of IGF1 were measured in blood samples collected from 397,380 participants from the UK Biobank, from 2006 through 2010. Incident cancer cases and cancer cases recorded first in death certificates were identified through linkage to national cancer and death registries. Complete follow-up was available through March 31, 2016. For the MR analyses, we identified genetic variants associated with circulating levels of IGF1 and IGFBP3. The association of these genetic variants with colorectal cancer was examined with 2-sample MR methods using genome-wide association study consortia data (52,865 cases with colorectal cancer and 46,287 individuals without [controls]) RESULTS: After a median follow-up period of 7.1 years, 2665 cases of colorectal cancer were recorded. In a multivariable-adjusted model, circulating level of IGF1 associated with colorectal cancer risk (hazard ratio per 1 standard deviation increment of IGF1, 1.11; 95% confidence interval [CI] 1.05-1.17). Similar associations were found by sex, follow-up time, and tumor subsite. In the MR analyses, a 1 standard deviation increment in IGF1 level, predicted based on genetic factors, was associated with a higher risk of colorectal cancer risk (odds ratio 1.08; 95% CI 1.03-1.12; P = 3.3 × 10). Level of IGFBP3, predicted based on genetic factors, was associated with colorectal cancer risk (odds ratio per 1 standard deviation increment, 1.12; 95% CI 1.06-1.18; P = 4.2 × 10). Colorectal cancer risk was associated with only 1 variant in the IGFBP3 gene region (rs11977526), which also associated with anthropometric traits and circulating level of IGF2.
In an analysis of blood samples from almost 400,000 participants in the UK Biobank, we found an association between circulating level of IGF1 and colorectal cancer. Using genetic data from 52,865 cases with colorectal cancer and 46,287 controls, a higher level of IGF1, determined by genetic factors, was associated with colorectal cancer. Further studies are needed to determine how this signaling pathway might contribute to colorectal carcinogenesis.
研究人员对人类进行了研究,以检测循环胰岛素样生长因子 1(IGF1)和胰岛素样生长因子结合蛋白 3(IGFBP3)水平与结直肠癌风险之间的关联,但结果并不一致。我们进行了补充血清学和孟德尔随机化(MR)分析,以确定 IGF1 或 IGFBP3 水平的变化是否与结直肠癌的发生发展有关。
研究人员在英国生物库中收集了 397380 名参与者的血液样本,并于 2006 年至 2010 年期间测量了血清 IGF1 水平。通过与国家癌症和死亡登记处的链接,确定了癌症病例和首次记录在死亡证明中的癌症病例。截至 2016 年 3 月 31 日,研究人员完成了完整的随访。对于 MR 分析,研究人员确定了与循环 IGF1 和 IGFBP3 水平相关的遗传变异。使用全基因组关联研究联盟数据(52865 例结直肠癌病例和 46287 例无(对照)个体),采用两样本 MR 方法,研究了这些遗传变异与结直肠癌的相关性。
中位随访 7.1 年后,记录了 2665 例结直肠癌病例。在多变量调整模型中,循环 IGF1 水平与结直肠癌风险相关(IGF1 每标准偏差增加的风险比,1.11;95%置信区间[CI],1.05-1.17)。按性别、随访时间和肿瘤亚部位进行分析,也观察到了类似的相关性。在 MR 分析中,根据遗传因素预测的 IGF1 水平每标准偏差增加,与结直肠癌风险增加相关(比值比 1.08;95%CI,1.03-1.12;P=3.3×10)。根据遗传因素预测的 IGFBP3 水平与结直肠癌风险相关(每标准偏差增加的比值比,1.12;95%CI,1.06-1.18;P=4.2×10)。IGFBP3 基因区域的 1 个变异(rs11977526)与结直肠癌风险相关,该变异也与人体测量特征和循环 IGF2 水平相关。
在对英国生物库近 400000 名参与者的血液样本进行分析时,研究人员发现 IGF1 循环水平与结直肠癌之间存在关联。使用 52865 例结直肠癌病例和 46287 例对照的遗传数据,通过遗传因素确定的 IGF1 水平升高与结直肠癌相关。需要进一步研究以确定该信号通路如何促进结直肠癌变。